FDA Grants Rare Pediatric Disease Designation to Atossa's (Z)-Endoxifen for Duchenne Muscular Dystrophy
The FDA granted Rare Pediatric Disease designation to Atossa Therapeutics' (Z)-endoxifen for treating Duchenne Muscular Dystrophy. The designation may qualify the drug for a valuable Priority Review Voucher upon approval. Atossa reported a net loss of $34.8 million for 2025 as it advances clinical development.
The U.S. Food and Drug Administration has granted Rare Pediatric Disease designation to (Z)-endoxifen for the treatment of Duchenne Muscular Dystrophy (DMD). The designation, announced on December 11, 2025, is reserved for serious or life-threatening diseases that primarily affect individuals from birth to 18 years of age.
Upon FDA approval of a qualifying marketing application, drugs with Rare Pediatric Disease designation may be eligible for a Priority Review Voucher. In the last 18–24 months, disclosed sales for such vouchers have ranged from $100 million to $160 million. The designation provides a regulatory framework and an enhanced level of interaction with the FDA as the company defines the clinical development path.
Atossa Therapeutics is a clinical-stage biopharmaceutical company. Its experimental drug (Z)-endoxifen is a potent Selective Estrogen Receptor Modulator/Degrader (SERM/D). The company's proprietary oral formulation has shown a favorable safety profile and pharmacology distinct from tamoxifen, including ER-targeted effects and PKC inhibition. (Z)-Endoxifen is not approved for any indication.
Preclinical data suggests (Z)-endoxifen's mechanism is differentiated because it does not target specific exon defects, potentially offering a broader treatment approach for the DMD patient population. Duchenne Muscular Dystrophy is a rare, progressive, X-linked neuromuscular disorder caused by mutations in the dystrophin gene, leading to muscle weakness and other complications. It is uniformly fatal, often in early adulthood.
The company has advanced (Z)-endoxifen through multiple Phase 2 trials in oncology, including the Karisma, EVANGELINE, RECAST, and I-SPY2 studies, which have reported promising efficacy signals. The Rare Pediatric Disease designation for DMD is part of Atossa's regulatory momentum, and the company is pursuing additional orphan drug designations in 2026.
In its 2025 financial results, Atossa Therapeutics reported zero revenue for the year ended December 31, 2025, and a net loss of $34.8 million. The company recorded an operating loss of $37.1 million, reflecting continued pre-revenue, development-stage operations and increased clinical spending. With no product revenue, the company relies on equity offerings, an at-the-market facility, grants, and collaborations to fund its near-term clinical operations.
The company has established a proprietary manufacturing process, qualified suppliers, and expanded leased office space to support development activities. Research and development investment increased, driving higher activity and enrollment across its neoadjuvant and breast density studies. Atossa Therapeutics' intellectual property portfolio for (Z)-endoxifen includes multiple recently issued U.S. patents and numerous pending applications worldwide.